Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

1YAT

IMPROVED CALCINEURIN INHIBITION BY YEAST FKBP12-DRUG COMPLEXES. CRYSTALLOGRAPHIC AND FUNCTIONAL ANALYSIS

Summary for 1YAT
Entry DOI10.2210/pdb1yat/pdb
DescriptorFK506 BINDING PROTEIN, 8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN (3 entities in total)
Functional Keywordsbinding protein
Biological sourceSaccharomyces cerevisiae (baker's yeast)
Cellular locationCytoplasm: P20081
Total number of polymer chains1
Total formula weight12842.65
Authors
Rotonda, J.,Becker, J.W. (deposition date: 1993-01-06, release date: 1993-10-31, Last modification date: 2024-02-14)
Primary citationRotonda, J.,Burbaum, J.J.,Chan, H.K.,Marcy, A.I.,Becker, J.W.
Improved calcineurin inhibition by yeast FKBP12-drug complexes. Crystallographic and functional analysis.
J.Biol.Chem., 268:7607-7609, 1993
Cited by
PubMed Abstract: The protein phosphatase calcineurin is the putative target for the immunosuppressive drug FK-506. The enzyme is inhibited by the complex of the drug with its intracellular receptor, the 12-kDa FK-506-binding protein (FKBP12), and the strength of inhibition usually correlates strongly with immunosuppressive potency. We find, however, that the complex of yeast FKBP12 with L-685,818, a well characterized antagonist of FK-506 immunosuppression, is a potent inhibitor of calcineurin. The corresponding human complex does not inhibit the enzyme, and both human and yeast complexes with FK-506 do inhibit. To understand the structural basis of these findings, we have determined the three-dimensional structure of the complex of yeast FKBP12 with FK-506 by x-ray crystallography, and have found that the structure of the yeast complex is strikingly similar to its human homolog. These observations indicate that specific sequence elements in the yeast protein provide stronger binding interactions with a heterologous calcineurin than do the corresponding elements in the human protein, and suggest structural modifications that may improve the potency of this class of immunosuppressants.
PubMed: 7681823
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.5 Å)
Structure validation

246704

PDB entries from 2025-12-24

PDB statisticsPDBj update infoContact PDBjnumon